

Gaia Pellegatta

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7293351/gaia-pellegatta-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10
papers

137
citations

5
h-index

11
g-index

11
ext. papers

163
ext. citations

2.2
avg, IF

1.76
L-index

#	Paper	IF	Citations
10	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020 , 73, 593-602	13.4	28
9	Usefulness of Pep-Test for Laryngo-Pharyngeal Reflux: A Pilot Study in Primary Care. <i>Korean Journal of Family Medicine</i> , 2020 , 41, 250-255	1.7	2
8	Improvement in Waldenström's Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals. <i>Annals of Hepatology</i> , 2018 , 17, 0-10	3.1	
7	Improvement in Waldenström's Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals. <i>Annals of Hepatology</i> , 2018 , 17, 1072-1077	3.1	2
6	Epidemiology and natural history of gastroesophageal reflux disease. <i>Minerva Gastroenterology</i> , 2017 , 63, 175-183	3	19
5	Complexity and diversity of gastroesophageal reflux disease phenotypes. <i>Minerva Gastroenterology</i> , 2017 , 63, 198-204	3	1
4	Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 1333-1341	5.5	15
3	Positive PET in a Patient With Esophageal Leiomyoma. <i>American Journal of Gastroenterology</i> , 2016 , 111, 767	0.7	2
2	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2016 , 111, 70-7	0.7	42
1	Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016 , 51, 1081-6	2.4	26